Spots Global Cancer Trial Database for iap antagonist
Every month we try and update this database with for iap antagonist cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
A Study of the Safety and Pharmacokinetics of GDC-0152, Administered Intravenously to Patients With Locally Advanced or Metastatic Malignancies | NCT00977067 | Solid Cancers | GDC-0152 | 18 Years - | Genentech, Inc. | |
A Study of the Safety and Pharmacokinetics of GDC-0152, Administered Intravenously to Patients With Locally Advanced or Metastatic Malignancies | NCT00977067 | Solid Cancers | GDC-0152 | 18 Years - | Genentech, Inc. | |
Pembrolizumab In Combination With Debio 1143 In Pancreatic and Colorectal Advanced/Metastatic Adenocarcinoma | NCT03871959 | Adenocarcinoma ... Adenocarcinoma ... Adenocarcinoma ... | Pembrolizumab DEBIO1143 | 18 Years - | Centre Leon Berard |